Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

254.28
+5.582.24%
Post-market: 254.280.00000.00%19:52 EDT
Volume:516.75K
Turnover:131.04M
Market Cap:16.51B
PE:17.38
High:255.85
Open:248.75
Low:248.55
Close:248.70
52wk High:265.05
52wk Low:121.40
Shares:64.91M
Float Shares:62.69M
Volume Ratio:1.04
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.44
PE(LYR):-43.54

Loading ...

Jazz director Bruce Cozadd disposes of $1.22 million Jazz Pharmaceuticals shares

Reuters
·
May 06

GUIDANCE: (JAZZ) Jazz Pharmaceuticals Expects Full Year 2026 Revenue Range $4.25B - $4.50B, vs. FactSet Est of $4.44B

MT Newswires Live
·
May 06

BRIEF-Jazz Pharmaceuticals Q1 Adjusted EPS USD 6.34 Vs. IBES Estimate USD 4.57

Reuters
·
May 06

Jazz Pharmaceuticals Plc: Company Reaffirms 2026 Revenue and Expense Guidance

THOMSON REUTERS
·
May 06

FOCUS-Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification

Reuters
·
Apr 30

Earning Preview: Jazz Pharmaceuticals PLC Q1 revenue is expected to decrease by 0.67%, and institutional views are cautious to neutral

Earnings Agent
·
Apr 28

TD Cowen Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Apr 27

Jazz Pharmaceuticals Announces FDA Acceptance And Priority Review Of Supplemental Biologics License Application For Ziihera®

Reuters
·
Apr 27

Jazz Pharma FDA wins priority review for Ziihera combos in first-line HER2+ GEA

Reuters
·
Apr 27

Jazz Pharmaceuticals Plc - FDA Sets Pdufa Date of August 25, 2026 for Ziihera Sbla

THOMSON REUTERS
·
Apr 27

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (Zanidatamab-Hrii) Combinations in First-Line Her2+ Locally Advanced or Metastatic Gea

THOMSON REUTERS
·
Apr 27

Jazz Pharmaceuticals Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Apr 22

Jazz Pharmaceuticals to report first-quarter results after market close

Reuters
·
Apr 22

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026

THOMSON REUTERS
·
Apr 22

Jazz spotlights Phase 3 HERIZON-GEA-01 PD-L1 subgroup data for Ziihera at ASCO

Reuters
·
Apr 22

Jazz Pharmaceuticals Is Maintained at Overweight by Barclays

Dow Jones
·
Apr 20

A Look At Jazz Pharmaceuticals (JAZZ) Valuation After New Neurology Data Plans At 2026 AAN Meeting

Simply Wall St.
·
Apr 16

Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says

MT Newswires Live
·
Apr 09

Jazz reports EpiCom analysis shows Epidiolex cuts behavioral problems in TSC seizures

Reuters
·
Apr 09

RBC Capital Remains a Buy on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Apr 08